Fulcrum Asset Management LLP Acquires New Holdings in Insmed, Inc. $INSM

Fulcrum Asset Management LLP acquired a new stake in shares of Insmed, Inc. (NASDAQ:INSM) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 9,676 shares of the biopharmaceutical company’s stock, valued at approximately $1,119,000.

A number of other institutional investors have also made changes to their positions in the company. Pictet Asset Management Holding SA lifted its position in shares of Insmed by 44.0% during the third quarter. Pictet Asset Management Holding SA now owns 1,757,541 shares of the biopharmaceutical company’s stock worth $200,845,000 after purchasing an additional 537,188 shares in the last quarter. Sei Investments Co. grew its holdings in Insmed by 56.8% during the 1st quarter. Sei Investments Co. now owns 1,395,794 shares of the biopharmaceutical company’s stock valued at $228,239,000 after purchasing an additional 505,624 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in Insmed during the 2nd quarter valued at $139,966,000. Assenagon Asset Management S.A. grew its holdings in Insmed by 480.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,266,788 shares of the biopharmaceutical company’s stock valued at $144,591,000 after purchasing an additional 1,048,518 shares in the last quarter. Finally, NWI Management LP grew its holdings in Insmed by 2.6% during the 1st quarter. NWI Management LP now owns 1,014,000 shares of the biopharmaceutical company’s stock valued at $165,809,000 after purchasing an additional 25,540 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on INSM shares. HC Wainwright assumed coverage on shares of Insmed in a research note on Wednesday, November 4th. They set a “buy” rating and a $220.00 price target on the stock. Guggenheim decreased their price objective on shares of Insmed from $205.00 to $201.00 and set a “buy” rating for the company in a research report on Monday, November 2nd. Mizuho set a $154.00 target price on Insmed in a research note on Thursday, October 29th. Raymond James Financial set a $173.00 price target on Insmed in a research note on Tuesday, October 20th. Finally, UBS Group reissued a “buy” rating on shares of Insmed in a report on Thursday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Insmed currently has a consensus rating of “Moderate Buy” and an average price target of $196.52.

Insider Buying and Selling

In other Insmed news, Director David Brennan sold 25,000 shares of the firm’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the completion of the transaction, the director directly owned 39,238 shares of the company’s stock, valued at $4,865,512. This trade represents a 38.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 2.10% of the stock is owned by company insiders.

Insmed Stock Up 1.1%

INSM stock opened at $120.75 on Thursday. Insmed, Inc. has a twelve month low of $90.39 and a twelve month high of $212.75. The company has a current ratio of 2.86, a quick ratio of 2.59 and a debt-to-equity ratio of 0.77. The company has a market capitalization of $26.49 billion, a P/E ratio of -42.82 and a beta of 0.83. The firm has a 50 day simple moving average of $111.10 and a 200-day simple moving average of $123.78.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). The company had revenue of $524.43 million during the quarter, compared to the consensus estimate of $500.36 million. Insmed had a negative return on equity of 96.38% and a negative net margin of 39.85%. The firm’s quarterly revenue was up 268.4% on a year-over-year basis. During the same quarter last year, the firm posted ($1.75) EPS. On average, equities research analysts predict that Insmed, Inc. will post -1.86 earnings per share for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.